Biogen

News

Biogen has started a new phase 3 trial that aims to extend the use of its Friedreich's ataxia drug Skyclarys to patients as young as two.

News

Sage Therapeutics has agreed to be acquired by Supernus Pharma in a deal valued at around $571 million.

News

Hopes rise for a new treatment option for people living with lupus, after UCB and Biogen reveal phase 3 data with their anti-CD40L antibody DZP.

News

The EU has approved Eisai and Biogen's Leqembi for a subset of patients with early-stage Alzheimer's disease, more than two years after it was filed.

News

A study has suggested early targeting of amyloid in the brains of people with inherited Alzheimer's can delay symptoms, but not all are convinced.

News

An observational study backed by Biogen has suggested that Apple smartphones and watches may be able to spot the signs of mild cognitive impairment.